Literature DB >> 15548703

Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.

Peter S Hammerman1, Casey J Fox, Ryan M Cinalli, Anne Xu, John D Wagner, Tullia Lindsten, Craig B Thompson.   

Abstract

Pim-2 is a transcriptionally regulated oncogenic kinase that promotes cell survival in response to a wide variety of proliferative signals. Deregulation of Pim-2 expression has been documented in several human malignancies, including leukemia, lymphoma, and multiple myeloma. Here, we show that the ability of Pim-2 to promote survival of cells is dependent on nuclear factor (NF)-kappaB activation. Pim-2 activates NF-kappaB-dependent gene expression by inducing phosphorylation of the oncogenic serine/threonine kinase Cot, leading to both augmentation of IkappaB kinase activity and a shift in nuclear NF-kappaB from predominantly p50 homodimers to p50/p65 heterodimers. Blockade of NF-kappaB function eliminates Pim-2-mediated survival in both cell lines and primary cells, and both Cot phosphorylation and expression are required for the prosurvival effects of Pim-2. Although Pim-2 cooperates with Myc to promote growth factor-independent cell proliferation, this feature is abrogated by NF-kappaB blockade. The ability of Pim-2 to serve as an oncogene in vivo depends on sustained NF-kappaB activity. Thus, the transcriptional induction of Pim-2 initiates a novel NF-kappaB activation pathway that regulates cell survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548703     DOI: 10.1158/0008-5472.CAN-04-2284

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

Review 2.  The survival kinases Akt and Pim as potential pharmacological targets.

Authors:  Ravi Amaravadi; Craig B Thompson
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 3.  Emerging roles for the non-canonical IKKs in cancer.

Authors:  R R Shen; W C Hahn
Journal:  Oncogene       Date:  2010-11-01       Impact factor: 9.867

4.  Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.

Authors:  Ke Ren; Wei Zhang; Yujun Shi; Jianping Gong
Journal:  Pathol Oncol Res       Date:  2009-10-12       Impact factor: 3.201

Review 5.  Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Authors:  Gabriela Brumatti; Marika Salmanidis; Paul G Ekert
Journal:  Cell Mol Life Sci       Date:  2010-02-16       Impact factor: 9.261

Review 6.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

7.  RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

Authors:  Riet van der Meer; Ha Yong Song; Seong-Hoon Park; Sarki A Abdulkadir; Meejeon Roh
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 8.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

9.  Bcl-2 blocks 2-methoxyestradiol induced leukemia cell apoptosis by a p27(Kip1)-dependent G1/S cell cycle arrest in conjunction with NF-kappaB activation.

Authors:  Christina Batsi; Soultana Markopoulou; Evangelos Kontargiris; Christiana Charalambous; Christoforos Thomas; Savvas Christoforidis; Panagiotis Kanavaros; Andreas I Constantinou; Kenneth B Marcu; Evangelos Kolettas
Journal:  Biochem Pharmacol       Date:  2009-03-27       Impact factor: 5.858

10.  Ectopic over-expression of oncogene Pim-2 induce malignant transformation of nontumorous human liver cell line L02.

Authors:  Ke Ren; Wentao Duan; Yujun Shi; Bo Li; Zuojin Liu; Jiangping Gong
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.